Sony has confirmed that it's shuttering Studio Liverpool, more famously known as Psygnosis. The publisher was founded in 1984 and is responsible for a legion of best-selling titles including Lemmings, Colony Wars, Destruction Derby, Wipeout and the Formula One games. In a statement, the company said that after a review of its "commercially viable" projects, it's focusing on projects in other parts of the business -- after slashing the studio's remit in a cost-cutting exercise in 2010. The facility is also the location of the company's European Quality Assurance team, which will reportedly remain in operation.
Atlantic City Officials are currently collaborating with local businesses to expand the ?Do AC? campaign.
Jerry Driendl, Getty Images
After initially being reported that the Atlantic City Alliance was taking legal action against local businesses that were using similar logos to promote and advertise, the Alliance has clarified that they are not taking any serious legal action, and are actually encouraging businesses to use similar slogans.
?The use of the ?Do AC? logo and slogan by partner businesses is actually encouraged by the Atlantic City Alliance,? Chief Communications and Strategy Officer Jeff Guaracino said.
The city has however sent out a number of cease and desist letters to many businesses for the sole purpose of allowing the city to help the businesses develop the brand. No further legal action is being pursued.
Atlantic City officials have been working with businesses on a case-by-case bases to help develop the brand and logo so that no trademarks are violated.
?The legal issue is working with each business so that they use the proper colors and sizes which are compliant with the style guide. We want to make sure that no business violates the trademark,? Guaracino said.
Since being launched in April by the Atlantic City Alliance, the ?Do AC? slogan has taken off in popularity. Over 100,000 5.5 inch in diameter magnets bearing the logo have been distributed since April, and have quickly become a staple on many Atlantic City cars.
The main purpose of the new slogan launch was to create a buzz around Atlantic City. Many local businesses have seen how successful the campaign has been and felt that piggybacking on the campaign would be create more exposure for both their businesses as well as the city.
Weston? is a neighboring community of Westport enjoying a close association with Westport and its considerable amenities, including a shared Chamber of Commerce.
Weston Town website
Demographics ? Town Profile School Information ? ? Board of Education ? ?School Reports Recreation ? ? Newcomers Club ? ??Parks & Rec? ? ?Library ? ? ?Aspetuck Land Trust? ? ?Devils Den Golf & Tennis ? Aspetuck Valley Country Club? ? ? Weston Field Club? ? ? Weston Racquet Club Equestrian Fairfield Bridle Trails Salko Farm & StableWeston Ra Local News Sources ? ?Weston Forum? ? ?The Patch ? ??Daily Voice Articles ??Connecticut Magazine ranks?Weston #2?best?city with population 10-15,000.
US Vice President Joe Biden will look his opponents in the eyes next week when he campaigns in Tampa, Florida during the first two days of the Republican National Convention there.
The Republican event, which runs from August 27 to 30, will see former Massachusetts governor Mitt Romney and his running mate Paul Ryan will be formally named candidates for the November 6 presidential election.
"On Monday, August 27 and Tuesday, August 28, Vice President Joe Biden will travel to the Tampa area and other cities for campaign events," the re-election campaign of Democratic President Barack Obama said in a brief statement.
Obama and Biden will be confirmed as the Democratic candidates at their party's convention in Charlotte, North Carolina, from September 4 to 6.
SAN FRANCISCO (AP) ? After three weeks of listening to technology experts, patent professionals and company executives debate the complicated legal claims of Apple Corp. and Samsung Electronics Co., a jury of nine men and women are set to decide one of the biggest technology disputes in history.
Apple is demanding Samsung pay it $2.5 billion and pull its most popular smartphones and computer tablets from the U.S. market after accusing the South Korean company of "ripping off" its iPhone and iPad technology. Samsung, in turn, is demanding Apple pay it $399 million for allegedly using Samsung's technology without proper payments in making the iconic iPhone and iPad.
Apple's damage demands, if awarded, would represent the largest patent verdict in the U.S. An appeals court last year overturned the largest award to date, a $1.8 billion judgment against pharmaceutical company Abbott Laboratories.
Apple and Samsung are the top-selling smartphone makers and combined account for more than half of global smartphone sales.
Barring a last-minute settlement, jurors are scheduled to hear the dueling companies' lawyers deliver closing arguments Tuesday in the San Jose federal courtroom of Judge Lucy Koh and they could begin deliberating late that afternoon, or more likely, Wednesday morning.
From the beginning, legal experts and Wall Street analysts have viewed Samsung as the underdog. To begin with, Apple's headquarters is a mere 10 miles from the courthouse and the jurors were picked from the heart of Silicon Valley where the company's late founder Steve Jobs is a revered technological pioneer.
And while the legal and technological issues may be complex, patent expert Alexander I. Poltorak says the case will likely boil down to whether jurors believe Samsung's products at issue look and feel almost identical to Apple's iPhone and iPad.
"Most jurors will probably say they look alike," said Poltorak, who is chief executive of General Patent Corp. The judge appears to agree.
The judge in June called Samsung's Galaxy 10.1 tablet computer "virtually indistinguishable" from Apple's iPad and banned its sale in the United States until the resolution of the case.
"There was some evidence that Samsung altered its design to make its product look more like Apple's," the judge found two months before the trial started.
To overcome that hurdle, Samsung's battalion of lawyers has been arguing that many of Apple's claims of innovation are either obvious ideas or were actually stolen ideas from Sony Corp. and others. Experts called that line of argument a high-risk strategy because of Apple's reputation as an innovator.
"Saying Apple is a copyist is going be a hard sell," said Ellen Brickman, a New York-based jury and trial consultant. "Apple changed the world when it came to computers. Apple changed the world when it came to phones. The fact that the iPhone and iPad are so popular shows people believe the products must be innovative. When you think of tech, you just don't think of Samsung."
Finally, Brickman and others argue that a foreign rival accused of stealing from a popular U.S. company like Apple during the tough economic climate faces an uphill battle with a "hometown" jury.
General Patent's Poltorak said a verdict in Apple's favor would cost Samsung "a lot of money," but wouldn't dramatically disrupt the smartphone markets. He predicted that Samsung engineers would quickly redesign the company's smartphone and computer tablets to compete with Apple if the Cupertino-based company won its lawsuit.
Apple lawyers argue there is almost no difference between Samsung's products and Apple's and presented Samsung's internal documents they say show it copied Apple's designs. Samsung lawyers countered that several other companies and inventors had previously developed much of the Apple technology at issue.
The U.S. trial is just the latest skirmish between the two over product designs. The two companies have been fighting in courts in Australia, the United Kingdom and Germany.
The case is one of some 50 lawsuits among myriad telecommunications companies jockeying for position in the burgeoning $219 billion market for smartphones and computer tablets.
VICTORIA ? The parents of three-year-old Hannah Day, a Victoria girl diagnosed with a rare form of cancer, say they will file a formal complaint with the Vancouver Island Health Authority.
They say their little girl was extremely ill, vomiting and unable to eat for weeks. But, a string of doctors sent them away, including doctors at Victoria General Hospital?s Emergency Department.
Dr. Rod Rassekh, an oncologist at B.C. Children?s Hospital says diagnosing cancer in children can be difficult. Rassekh says Hannah?s cancer it is often found when tumours grow to a point the stomach becomes enlarged.
Her mother is angry it took so long to get to her daughter into treatment. Brooke Ervin says doctor after doctor told her nothing was wrong. Ervin says Hannah started showing signs of being ill in mid June; she was vomiting and unable to eat.
The family visited a number of walk-in clinics in the following weeks, but each time they were given a different explanation for what was wrong. It turns out, none were correct.
On July 26th Ervin took Hannah to the emergency department at Victoria General Hospital. Three hours later she was released with instructions to follow up with her family doctor
?They said it was bad posture,? says Ervin.
When Hannah?s symptoms got worse, her family doctor told Ervin to rush her daughter back to emergency at VGH and suggested an emergency ultra-sound.
?But they didn?t do an emergency ultra-sound,? Ervin explains.
The Vancouver Island Health Authority released the following treatment timeline CTV News:
August 3rd, 2012
3:15pm ? Hannah arrives at VGH and immediately triaged as ?critical.? 3:30pm ? Hannah is seen by a doctor 6:00pm ? An X-ray is taken. 11:30pm ? Doctors ordered an ultra sound.
August 4th, 2012
1:30am ? Hannah is admitted to the paediatric ward. 9:30am ? Hannah receives an ultra-sound. 2:30pm ? The family learns Hannah has a mass in her stomach 11:30pm ? Hannah is flown to B.C. Children?s Hospital
The NDP is calling on the health authority to complete a full review of the case. But, VIHA says it cannot act, unless it receives a complaint from the family. Hannah?s family says that complaint is coming, but their first priority is Hannah, and supporting her during, what is expected to be, a year of chemotherapy.
VIHA says it is required by law to respond and that could include a meeting with doctors and family to address concerns.
Hannah?s diagnosis is just the latest in a series of tragedies for her family. A fire in January 2011 gutted the family business and later that year, Hannah?s grandfather died from a heart attack. Now they family is struggling to make ends meet as keep a home in Victoria and stay with Hannah at the hospital.
To help the family survive, friends are stepping forward to raise money, setting up a Facebook page ?Help Little Hannah Get Cancer Free.?
Follow Stephen Andrew on Twitter: http://www.twitter.com/CTVNewsStephen
A material to rejuvenate aging and diseased human vocal cordsPublic release date: 20-Aug-2012 [ | E-mail | Share ]
Contact: Michael Bernstein
m_bernstein@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6042
Michael Woods
m_woods@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6293
American Chemical Society
PHILADELPHIA, Aug. 20, 2012 A new made-in-the-lab material designed to rejuvenate the human voice, restoring the flexibility that vocal cords lose with age and disease, is emerging from a collaboration between scientists and physicians, a scientist heading the development team said here today.
That's just one of several innovations that Robert Langer, Sc.D., discussed in delivering the latest Kavli Foundation Innovations in Chemistry Lecture at the 244th National Meeting & Exposition of the American Chemical Society (ACS). More than 14,000 scientists and others are expected to attend the meeting, which features 8,600 reports on new advances in science and other topics. The sessions continue through Thursday in the Pennsylvania Convention Center and downtown hotels.
Langer heads a team of almost 100 in laboratories at the Massachusetts Institute of Technology (MIT), one of the world's largest academic research laboratories. He holds, or has applied for, more than 800 patents, and has founded or co-founded numerous companies, with honors that include the ACS' 2012 Priestley Medal, the highest honor of the world's largest scientific society.
The artificial vocal cord material, the first designed to restore lost flexibility in human vocal cords, results from an ongoing effort to produce artificial tissues in the lab, Langer explained. Lost flexibility in the vocal cords, due to the effects of aging or disease, is a major factor in the voice loss that affects 18 million people in the United States alone.
"The synthetic vocal cord gel has similar properties as the material found in human vocal cords and flutters in response to air pressure changes, just like the real thing," explained Langer, who is the David H. Koch Institute Professor at MIT.
The vocal cords are two folds in the "voice box" that vibrate, or come together and away from each other very quickly to produce puffs of air that help form sounds. They function in much the same way as a reed in a saxophone. The cords consist of layers of muscle, ligament and a membrane. A layer between the ligament and the membrane is very flexible, and that flexibility and pliability is critical for speech.
But when someone, such as a teacher, a politician or a performer, overuses their voice, scar tissue develops. The same thing happens when a person gets older, accounting for the lower volume and hoarseness often apparent in older people. Cancer or having a tube inserted in the throat for medical procedures also can damage the cords. Scar tissue is stiff, and scarring leaves a person with a hoarse, breathy voice.
"About 90 percent of human voice loss is because of lost pliability," said Steven Zeitels, M.D., F.A.C.S., Langer's collaborator on the project. Zeitels is the Eugene B. Casey Professor at Harvard Medical School and Director of the Massachusetts General Hospital Voice Center. His patients include singers Julie Andrews of The Sound of Music fame, who lost her full vocal range after surgery done elsewhere in 1997, Steven Tyler of Aerosmith and Adele. "I recognized this need in my practice over the years, after seeing many patients with voice problems. I went to Bob Langer because I knew he could help design a material that would ultimately help patients speak and sing again. Currently, no treatments exist to restore vocal cord flexibility."
The material had to be very flexible and be able to vibrate just like human vocal cords. After trying numerous candidates, Langer's team settled on polyethylene glycol 30 (PEG30), which is already used in personal care creams and in medical devices and drugs approved by the U.S. Food and Drug Administration (FDA), as a starting material and created polymers based on it. The PEG30 gel can flutter at a rate of 200 times per second, which is a normal rate for a woman speaking in a conversation. Watch a video of the artificial vocal cord gel in action here.
A physician would inject the gel into a patient's vocal cords. Patients would receive different formulations, depending on how they use their voices. The most stable version is highly "cross-linked," which means the molecules of PEG are more tightly stitched together than in other versions. That makes the material a little bit rigid, but it would still help restore someone's speaking voice. A singer, however, would likely receive a formulation that is more loosely stitched together, or less cross-linked, which is more flexible to allow the patient to hit high notes. The gel degrades over time, so patients would receive two to five injections per year, estimated Zeitels.
Tests in animals suggest that the material is safe, and human trials will hopefully begin in mid-2013. Some of Zeitels' patients, such as Andrews, have formed a nonprofit organization called The Voice Health Institute, which funds Langer and Zeitels' research on the vocal cord biomaterial.
Artificial vocal cords are just one artificial tissue in development in Langer's lab. He described work on building intestinal, spinal cord, pancreatic and heart tissue in the laboratory with many different types of materials. Among them: Nanowires (which are about a tenth the diameter of a human hair) and something called "biorubber."
"It's hard to know when they will be ready for clinical use," Langer said. "But In Vivo Therapeutics hopes to start clinical trials for the spinal cord tissue we've developed within the next year."
Langer also recently developed a pacemaker-sized microchip that delivers just the right amount of medication at just the right time, potentially allowing thousands of patients to ditch painful needles forever. A clinical trial of the device, implanted in women with osteoporosis, has just concluded and showed that it was safe to use. The device released osteoporosis medication when it received a signal from a computer. It worked just as well as daily shots of the drug. MicroCHIPS, Inc., a company that Langer co-founded, will commercialize the remote-controlled microchip.
Another way to make medicines more effective is to make sure they go exactly to the location where they are needed; this reduces harmful side effects. Langer's targeted nanoparticles can do just that. A clinical trial run by BIND Biosciences, another company co-founded by Langer, recently found that these nanoparticles are safe in humans. The particles have a homing molecule on them that targets them to prostate cancer cells or cancer blood vessels, and they deliver an anti-cancer medication called docetaxel. All of the materials, including the drug, are already approved by the FDA.
Langer said that the chemical engineering field, which marries chemistry and engineering to make useful devices and other substances, is booming. "There are all kinds of advances happening in drug delivery, new vaccines and immunotherapies, tissue engineering, nanotherapies and nanodiagnostics," he said.
Watch a video here for more information about Langer's innovations.
Langer acknowledged funding from the National Institutes of Health and the National Cancer Institute.
Sponsored by The Kavli Foundation, a philanthropic organization that supports basic scientific research, the lectures are designed to address the urgent need for vigorous, "outside the box" thinking by scientists as they tackle the world's mounting challenges, including climate change, emerging diseases and water and energy shortages.
"We are dedicated to advancing science for the benefit of humanity, promoting public understanding of scientific research and supporting scientists and their work," said Kavli Foundation President Robert W. Conn in a statement. "The Kavli Foundation Innovations in Chemistry Lecture program at the ACS national meetings fits perfectly with our commitment to support groundbreaking discovery and promote public understanding."
The Kavli lectures debuted at the Anaheim meeting in March 2011 and will continue through 2013. They will address the urgent need for vigorous, new, "outside-the-box"- thinking, as scientists tackle many of the world's mounting challenges like climate change, emerging diseases and water and energy shortages. The Kavli Foundation, an internationally recognized philanthropic organization known for its support of basic scientific innovation, agreed to sponsor the lectures in conjunction with ACS in 2010.
###
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
Abstract
Advanced drug delivery systems are having an enormous impact on human health. We start by discussing our early research on developing the first polymeric controlled release systems for macromolecules and their use in the isolation of angiogenesis inhibitors and how this led to numerous new therapies. We then discuss new ways of using nanotechnology based systems to deliver DNA and siRNA. Approaches for creating new biomaterials are then evaluated and examples where such materials are used in brain cancer and shape memory applications are discussed. Finally, by combining mammalian cells, including stem cells, with synthetic polymers, new approaches for engineering tissues are being developed that may someday help in treating various diseases. Examples in the areas of cartilage, skin and spinal cord repair
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
A material to rejuvenate aging and diseased human vocal cordsPublic release date: 20-Aug-2012 [ | E-mail | Share ]
Contact: Michael Bernstein
m_bernstein@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6042
Michael Woods
m_woods@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6293
American Chemical Society
PHILADELPHIA, Aug. 20, 2012 A new made-in-the-lab material designed to rejuvenate the human voice, restoring the flexibility that vocal cords lose with age and disease, is emerging from a collaboration between scientists and physicians, a scientist heading the development team said here today.
That's just one of several innovations that Robert Langer, Sc.D., discussed in delivering the latest Kavli Foundation Innovations in Chemistry Lecture at the 244th National Meeting & Exposition of the American Chemical Society (ACS). More than 14,000 scientists and others are expected to attend the meeting, which features 8,600 reports on new advances in science and other topics. The sessions continue through Thursday in the Pennsylvania Convention Center and downtown hotels.
Langer heads a team of almost 100 in laboratories at the Massachusetts Institute of Technology (MIT), one of the world's largest academic research laboratories. He holds, or has applied for, more than 800 patents, and has founded or co-founded numerous companies, with honors that include the ACS' 2012 Priestley Medal, the highest honor of the world's largest scientific society.
The artificial vocal cord material, the first designed to restore lost flexibility in human vocal cords, results from an ongoing effort to produce artificial tissues in the lab, Langer explained. Lost flexibility in the vocal cords, due to the effects of aging or disease, is a major factor in the voice loss that affects 18 million people in the United States alone.
"The synthetic vocal cord gel has similar properties as the material found in human vocal cords and flutters in response to air pressure changes, just like the real thing," explained Langer, who is the David H. Koch Institute Professor at MIT.
The vocal cords are two folds in the "voice box" that vibrate, or come together and away from each other very quickly to produce puffs of air that help form sounds. They function in much the same way as a reed in a saxophone. The cords consist of layers of muscle, ligament and a membrane. A layer between the ligament and the membrane is very flexible, and that flexibility and pliability is critical for speech.
But when someone, such as a teacher, a politician or a performer, overuses their voice, scar tissue develops. The same thing happens when a person gets older, accounting for the lower volume and hoarseness often apparent in older people. Cancer or having a tube inserted in the throat for medical procedures also can damage the cords. Scar tissue is stiff, and scarring leaves a person with a hoarse, breathy voice.
"About 90 percent of human voice loss is because of lost pliability," said Steven Zeitels, M.D., F.A.C.S., Langer's collaborator on the project. Zeitels is the Eugene B. Casey Professor at Harvard Medical School and Director of the Massachusetts General Hospital Voice Center. His patients include singers Julie Andrews of The Sound of Music fame, who lost her full vocal range after surgery done elsewhere in 1997, Steven Tyler of Aerosmith and Adele. "I recognized this need in my practice over the years, after seeing many patients with voice problems. I went to Bob Langer because I knew he could help design a material that would ultimately help patients speak and sing again. Currently, no treatments exist to restore vocal cord flexibility."
The material had to be very flexible and be able to vibrate just like human vocal cords. After trying numerous candidates, Langer's team settled on polyethylene glycol 30 (PEG30), which is already used in personal care creams and in medical devices and drugs approved by the U.S. Food and Drug Administration (FDA), as a starting material and created polymers based on it. The PEG30 gel can flutter at a rate of 200 times per second, which is a normal rate for a woman speaking in a conversation. Watch a video of the artificial vocal cord gel in action here.
A physician would inject the gel into a patient's vocal cords. Patients would receive different formulations, depending on how they use their voices. The most stable version is highly "cross-linked," which means the molecules of PEG are more tightly stitched together than in other versions. That makes the material a little bit rigid, but it would still help restore someone's speaking voice. A singer, however, would likely receive a formulation that is more loosely stitched together, or less cross-linked, which is more flexible to allow the patient to hit high notes. The gel degrades over time, so patients would receive two to five injections per year, estimated Zeitels.
Tests in animals suggest that the material is safe, and human trials will hopefully begin in mid-2013. Some of Zeitels' patients, such as Andrews, have formed a nonprofit organization called The Voice Health Institute, which funds Langer and Zeitels' research on the vocal cord biomaterial.
Artificial vocal cords are just one artificial tissue in development in Langer's lab. He described work on building intestinal, spinal cord, pancreatic and heart tissue in the laboratory with many different types of materials. Among them: Nanowires (which are about a tenth the diameter of a human hair) and something called "biorubber."
"It's hard to know when they will be ready for clinical use," Langer said. "But In Vivo Therapeutics hopes to start clinical trials for the spinal cord tissue we've developed within the next year."
Langer also recently developed a pacemaker-sized microchip that delivers just the right amount of medication at just the right time, potentially allowing thousands of patients to ditch painful needles forever. A clinical trial of the device, implanted in women with osteoporosis, has just concluded and showed that it was safe to use. The device released osteoporosis medication when it received a signal from a computer. It worked just as well as daily shots of the drug. MicroCHIPS, Inc., a company that Langer co-founded, will commercialize the remote-controlled microchip.
Another way to make medicines more effective is to make sure they go exactly to the location where they are needed; this reduces harmful side effects. Langer's targeted nanoparticles can do just that. A clinical trial run by BIND Biosciences, another company co-founded by Langer, recently found that these nanoparticles are safe in humans. The particles have a homing molecule on them that targets them to prostate cancer cells or cancer blood vessels, and they deliver an anti-cancer medication called docetaxel. All of the materials, including the drug, are already approved by the FDA.
Langer said that the chemical engineering field, which marries chemistry and engineering to make useful devices and other substances, is booming. "There are all kinds of advances happening in drug delivery, new vaccines and immunotherapies, tissue engineering, nanotherapies and nanodiagnostics," he said.
Watch a video here for more information about Langer's innovations.
Langer acknowledged funding from the National Institutes of Health and the National Cancer Institute.
Sponsored by The Kavli Foundation, a philanthropic organization that supports basic scientific research, the lectures are designed to address the urgent need for vigorous, "outside the box" thinking by scientists as they tackle the world's mounting challenges, including climate change, emerging diseases and water and energy shortages.
"We are dedicated to advancing science for the benefit of humanity, promoting public understanding of scientific research and supporting scientists and their work," said Kavli Foundation President Robert W. Conn in a statement. "The Kavli Foundation Innovations in Chemistry Lecture program at the ACS national meetings fits perfectly with our commitment to support groundbreaking discovery and promote public understanding."
The Kavli lectures debuted at the Anaheim meeting in March 2011 and will continue through 2013. They will address the urgent need for vigorous, new, "outside-the-box"- thinking, as scientists tackle many of the world's mounting challenges like climate change, emerging diseases and water and energy shortages. The Kavli Foundation, an internationally recognized philanthropic organization known for its support of basic scientific innovation, agreed to sponsor the lectures in conjunction with ACS in 2010.
###
The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 164,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
Note to journalists: Please report that this research was presented at a meeting of the American Chemical Society.
Abstract
Advanced drug delivery systems are having an enormous impact on human health. We start by discussing our early research on developing the first polymeric controlled release systems for macromolecules and their use in the isolation of angiogenesis inhibitors and how this led to numerous new therapies. We then discuss new ways of using nanotechnology based systems to deliver DNA and siRNA. Approaches for creating new biomaterials are then evaluated and examples where such materials are used in brain cancer and shape memory applications are discussed. Finally, by combining mammalian cells, including stem cells, with synthetic polymers, new approaches for engineering tissues are being developed that may someday help in treating various diseases. Examples in the areas of cartilage, skin and spinal cord repair
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Edge Online, CVG, Joystiq | 
GRrcade, Eurogamer | Email this | Comments
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tPbQ8GsMlBxDMT8NvaFMKkRB2dH2VEf-ESvYGTSif6I5_tUx4SnDBlByYAn31_vDjY6acpmqadbinSO580S1yEWJVEGIh6VsZbeOGrFe0=s0-d){kind=small}
Public release date: 20-Aug-2012
Share ]